

EU HTA Regulation 2027-2028

Member State perspective: BE

Marc VAN DE CASTEELE

PhD physician-specialist internal medicine,
pharmaceutical medicine and clinical pharmacology

HTA-team pharmaceuticals

Dept. Pharmaceutical Policy,


head: Francis ARICKX



Presentation only about pharmaceuticals


- Preferentially national submissions once JCA report is publicly available
- Preferentially no outdated JCA reports
- Bilingual national reports English-Dutch or English-French

- National assessments post-JCA



to be added: BE clinical pathways, added clinical value, pharmacoeconomics, budget impact ...

- National appraisals post-JCA



Feed: Mixed JCA/national HTA

Conclusions HAS & ZIN

Beneluxa (*work in progress*)

Early discussion points for JCA revision 2028

- (co-)authorship: how to plan ?
- non authorship: full agenda's Subgroup JCA
- human resources for above
-